-
Mashup Score: 1Cervical Cancer: A Preventable Global Health Crisis for Women - 10 day(s) ago
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 20
In the BEV1L study, which used data from a US-nationwide, electronic health record–derived, deidentified database of patients with epithelial ovarian cancer, the real-world clinical benefit of adding…
Categories: General Medicine NewsTweet-
These real-world results support clinical trial data suggesting the benefit of adding bevacizumab to 1L chemotherapy may be limited to patients with high-risk prognostic factors. More from Dr. Linda Duska of @UvaDOM et al: https://t.co/vzJ3mQDoHM @OncoAlert @WileyOnc_Hem #gyncsm https://t.co/6tl3mMWTt3
-
-
Mashup Score: 4
Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
WATCH: Toon Van Gorp, MD, PhD, from @UZLeuven discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer. #gyncsm https://t.co/zgKQyotBpK
-
-
Mashup Score: 9PARP Inhibitors Show Promising Response and Clinical Benefit in BRCA-Altered Uterine Leiomyosarcoma - 1 month(s) ago
Patients with BRCA-altered uterine leiomyosarcoma treated with PARP inhibitors demonstrated encouraging outcomes.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Patients with BRCA-altered uterine leiomyosarcoma treated with PARP inhibitors demonstrated encouraging outcomes, according to a small retrospective study published in JCO Precision Oncology. #gyncsm https://t.co/WdiMgKU5oQ
-
-
Mashup Score: 1Avutometinib/Defactinib Appears Tolerable in KRAS-Mutant LGSOC - 1 month(s) ago
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Approximately 10% of patients with KRAS-mutated low-grade serous ovarian cancer discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial. #gyncsm https://t.co/aMXgRQls1Q
-
-
Mashup Score: 20
In the BEV1L study, which used data from a US-nationwide, electronic health record–derived, deidentified database of patients with epithelial ovarian cancer, the real-world clinical benefit of adding…
Categories: General Medicine NewsTweet-
These real-world results support clinical trial data suggesting the benefit of adding bevacizumab to 1L chemotherapy may be limited to patients with high-risk prognostic factors. More from Dr. Linda Duska of @UvaDOM et al: https://t.co/vzJ3mQDoHM @OncoAlert @WileyOnc_Hem #gyncsm https://t.co/6tl3mMWTt3
-
-
Mashup Score: 2FDA Approves At-Home Cervical Cancer Screening Kit - 1 month(s) ago
Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
The FDA has approved the Teal Wand™, an at-home vaginal sample self-collection device, for cervical cancer screening. #gyncsm https://t.co/mNXJvTACfA
-
-
Mashup Score: 1
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Investigators concluded that avutometinib at 1.6 mg would not be pursued as a starting dose in the treatment of those with recurrent low grade serous ovarian cancer. #gyncsm https://t.co/EKxeshRjOc
-
-
Mashup Score: 5Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer - 2 month(s) ago
In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin demonstrated encouraging responses, particularly in patients with ovarian cancer with low to medium FRα expression. #gyncsm https://t.co/ZScgtviOgb
-
-
Mashup Score: 0Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer - 2 month(s) ago
Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
The phase 3 KEYNOTE-B96 trial assessing pembrolizumab plus paclitaxel with or without bevacizumab reached the primary end point of PFS among patients with platinum-resistant ovarian cancer across the all-comer and PD-L1–positive populations. #gyncsm https://t.co/r2uO5tn8t1 https://t.co/GxsWASy726
-
Linda Duska, MD, FASCO, MPH, (@LDuska) discusses the unmet needs in the cervical cancer space & what prompted the KEYNOTE-A18 study of pembrolizumab in addition to chemoradiation for the treatment of locally advanced cervical cancer. #gyncsm | @uvamedicine https://t.co/EooIXy2suA